LA
JOLLA, Calif., Oct. 30,
2024 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica"
or the "Company") (Nasdaq: CALC), a clinical-stage
biopharmaceutical company focused on developing novel calcium
release-activated calcium ("CRAC") channel inhibition therapies for
acute and chronic inflammatory and immunologic illnesses, today
announced that it has commenced an underwritten public
offering of its shares of common stock.
All of the shares to be sold in the underwritten public offering
are to be sold by the Company. In connection with the proposed
offering, the Company expects to grant the underwriter a 30-day
option to purchase up to an additional 15% of the shares of its
common stock sold in the public offering. The offering is
subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or
the actual size or terms of the offering.
Jones is acting as the sole book-running manager for the
offering.
The underwritten public offering is being made pursuant to a
shelf registration statement on Form S-3 (File No. 333-273949)
(including a base prospectus) previously filed with the Securities
and Exchange Commission (the "SEC") on August 11, 2023 and declared effective by the SEC
on August 18, 2023. A preliminary
prospectus supplement and the accompanying prospectus relating to
and describing the terms of the underwritten public offering will
be filed with the SEC and will be available on the SEC's website at
www.sec.gov. When available, electronic copies of the preliminary
prospectus supplement and the accompanying prospectus relating to
the underwritten public offering may also be obtained by
contacting: JonesTrading Institutional Services LLC,
Attention: Equity Capital Markets, 325 Hudson Street, 6th Floor
New York, New York 10013; email:
ecm@jonestrading.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or
jurisdiction.
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic diseases.
CalciMedica's proprietary technology targets the inhibition of CRAC
channels to modulate the immune response and protect against tissue
cell injury, with the potential to provide therapeutic benefits in
life-threatening inflammatory and immunologic diseases for which
there are currently no approved
therapies. CalciMedica's lead product candidate Auxora™
has demonstrated positive and consistent clinical results in
multiple completed efficacy clinical trials. CalciMedica has
announced data for a Phase 2b trial
(called CARPO – NCT04681066) in patients with AP with SIRS and
completed a Phase 2 trial (called CARDEA – NCT04345614) in
patients with COVID pneumonia. The Company is currently conducting
a Phase 2 trial (called KOURAGE – NCT06374797) in patients
with AKI with associated AHRF with data expected in 2025 and
continuing to support the ongoing Phase 1/2 trial (called CRSPA
– NCT04195347) in patients with AIPT with data expected in
2025. CalciMedica was founded by scientists from Torrey Pines
Therapeutics and the Harvard CBR Institute for Biomedical
Research, and is headquartered in La Jolla, CA.
Forward-Looking Statements
Any statements in this
press release about future expectations, plans and prospects for
CalciMedica, including statements about the timing, terms and
completion of the underwritten public offering, and other
statements containing the words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict,"
"project," "target," "potential," "will," "would," "could,"
"should," "continue," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: CalciMedica's
inability, or the inability of the underwriter, to satisfy the
conditions to closing for the proposed underwritten public
offering; and economic, business, competitive, and/or
regulatory factors affecting the business of CalciMedica generally.
Additional risks and uncertainties that could cause actual outcomes
and results to differ materially from those contemplated by the
forward-looking statements are included under the caption "Risk
Factors" in CalciMedica's Quarterly Report on Form 10-Q for the
quarter ended June 30, 2024 filed
with the SEC on August 12, 2024, and
other filings CalciMedica makes with the SEC from time to time and
available at www.sec.gov. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. CalciMedica undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made, except as required by
law.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-proposed-public-offering-of-common-stock-302292103.html
SOURCE CalciMedica, Inc.
